Results 91 to 100 of about 2,141 (187)

Efficacy and safety of abrocitinib in biologic-exposed versus biologic-naive patients with moderate-to-severe atopic dermatitis

Abrocitinib, an oral once-daily Janus kinase 1 selective inhibitor, is being investigated for the treatment of moderate-to-severe atopic dermatitis (AD).
Gooderham, M., Strober, B., Chan, G., Guttman-Yassky, E., Biswas, P., Ardern-Jones, M., Levenberg, M., Watkins, M.   +7 more
core   +1 more source

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy

Dermatology and Therapy
Introduction A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe atopic ...
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, James Del Rosso, Linda Stein Gold, Erin Johansson, Martin Dossenbach, Gaia Gallo, Buelent Akmaz, Marta Casillas, Andrei Karlsson, Tristan Curteis, Raj Chovatiya   +19 more
doaj   +1 more source

Abrocitinib: 1-Year Real-Life Experience From the French OMCCI Registry

Abrocitinib is a selective inhibitor of Janus kinase 1 approved to treat moderate-to-severe atopic dermatitis (AD). Phase 3 clinical trials have demonstrated the efficacy and safety of abrocitinib; nevertheless, there is a need for real-world patient ...
Cinotti E., Cartocci A., Rubegni P., Becherel P. A., Perrot J. -L., Reguiai Z., Esteve E., D'Onghia M., Calabrese L., Maccari F., Boulard C., Fougerousse A. C.   +11 more
core   +1 more source

The therapeutic effect of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol on chemically induced atopic dermatitis

Scientific Reports
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease worldwide. However, it is still urgent to develop innovative treatments that can effectively manage refractory patients with unpredictable chronic disease courses. In this study,
Su-Hyun Shin, Yu-Jin Kim, Su-Jin Kim, Guen Tae Kim, Hyowon Lee, Eun Young Kim, Se Hee Lee, Ki-Young Sohn, Jae Wha Kim, Jae Sam Lee   +9 more
doaj   +1 more source

Successful treatment of refractory generalized granuloma annulare with abrocitinib

Dermatology Reports
Dear Editor, Granuloma annulare is a chronic inflammatory skin disorder characterized by annular dermal papules and plaques. While localized forms often resolve spontaneously, generalized granuloma annulare tends to persist and frequently proves resistant to conventional therapies.
Caterina Mariarosaria, Giorgio, Anna, Balato, Gaetano, Licata, Vittorio, Tancredi, Giuseppe, Argenziano, Eugenia Veronica, Di Brizzi   +5 more
openaire   +2 more sources

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL

Journal of Dermatological Treatment
Background JADE REAL was a global, prospective, multicenter, open-label expanded access protocol study that integrated the rigorous follow-up, safety, and efficacy assessments of a clinical trial with dosing flexibility and ability to use concomitant ...
Raj Chovatiya, Matthew Zirwas, Melinda J. Gooderham, Christine Bangert, Rodney Sinclair, Marjolein de Bruin-Weller, Stephan Weidinger, Carmen Tsang, Caitriona McCarthy, Andrew Selfridge, Pinaki Biswas, Herwig Koppensteiner, Claire Feeney, Sara Ramaker, Gary Chan   +14 more
doaj   +1 more source

Correction to: Abrocitinib: First Approval

Drugs, 2022
Deeks, Emma D., Duggan, Sean
openaire   +1 more source

Reversible azoospermia associated with the selective JAK1 inhibitor abrocitinib: a case report

Objective To describe a case of reversible azoospermia temporally associated with abrocitinib treatment in a man with severe atopic dermatitis (AD) and discuss its potential implications for male reproductive safety.
Aldo Eugenio Calogero, Giuseppe Seminara, Rossella Cannarella, Antonio Aversa   +3 more
core   +1 more source

JAK-1 inhibitors in the management of atopic dermatitis in patients over 65 years old: a descriptive cohort study

Scientific Reports
Atopic dermatitis (AD) can affect older adults. Janus kinase inhibitors (JAK-1 inhibitors), such as upadacitinib and abrocitinib, have emerged as effective treatments for moderate-to-severe AD.
Jiayue Zheng, Karla Robles-Velasco, Sonia Sharma, Isabel Canzi Almada de Souza Lima, Veronica Ferris Pasquini, Rodrigo G. Ducati, Hermenio Lima   +6 more
doaj   +1 more source

Refractory pityriasis rubra pilaris treated with abrocitinib

Dermatology Reports
Pityriasis rubra pilaris is a rare idiopathic papulosquamous disorder that significantly impacts quality of life and is often refractory to conventional therapies. This study presents a case of successful treatment with an abrocitinib JAK1 inhibitor after several conventional and biologic therapies failed.
openaire   +3 more sources